Hu5F9‐G4 tightly associates with human CD47, obstructs the CD47–SIRPα interaction, amplifies phagocytic activity, and facilitates the engulfment of primary acute myelogenous leukaemia(AML) cells in vitro. It eradicates human AML in xenograft models and collaborates synergistically with rituximab to eliminate non‐hodgkin lymphoma(NHL) xenografts. Here, CD47 is linked to Hodgkins lymphoma.